PET imaging of multidrug resistance in tumors using 18F-fluoropaclitaxel.
PET imaging of multidrug resistance in tumors using 18F-fluoropaclitaxel.
复制标题
DOI：
10.2174/156802610792928077
复制
发表时间：
2010
影响因子：
3.4
通讯作者：
Kiesewetter DO
中科院分区：
文献类型：
--
作者：
Kurdziel KA;Kiesewetter DO
The failure of solid tumors to respond to chemotherapy is a complicated and clinically frustrating issue. The ability to predict which tumors will respond to treatment could reduce the human and monetary costs of cancer therapy by allowing pro-active selection of a chemotherapeutic to which the tumor does not express resistance. PET/CT imaging with a radiolabeled form of paclitaxel, F-18 fluoropaclitaxel (FPAC), may be able to predict the uptake of paclitaxel in solid tumors, and as a substrate of P-glycoprotein, it may also predict which tumors exhibit multidrug resistance (MDR), a phenotype in which tumors fail to respond to a wide variety of chemically unrelated chemotherapeutic agents. This article reviews the synthetic, preclinical and early human data obtained during the development phase of this promising new radio-pharmaceutical.
